ArticleFrontiers in bioengineering and biotechnology2026
Rapid and reagent-free screening of occult hepatitis B virus infection based on plasma Vis-NIR spectral pattern recognition.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Occult hepatitis B virus infection (OBI) is a specific form of hepatitis B virus (HBV) infection characterized by testing negative for Hepatitis B surface antigen (HBsAg) with the presence of HBV DNA in the blood. Due to the complexity and high cost of HBV DNA testing, which is rarely included in routine physical examinations, leading to underdiagnosis of OBI. In this study, plasma visible-near-infrared (Vis-NIR) spectroscopy pattern recognition was employed to develop the discriminant analysis models for distinguishing between OBI from healthy (normal controls) plasma. Methods: A total of 444 plasma samples from voluntary blood donors (OBI 204, normal controls 240) were collected, and their Vis-NIR spectra were measured. The samples were rigorously divided into training, prediction, and independent external validation sets. Partial least squares-discriminant analysis (PLS-DA) and k-nearest neighbor (kNN) were used as spectral classifiers; standard normal variate (SNV) and norris derivative filtering (NDF) were applied for spectral preprocessing. The integrated algorithm combining separation degree priority combination (SDPC) with wavelength step-by-step phase-out (WSP) was utilized for the optimal wavelength selection. Results: The plasma spectral discriminant models for OBI and normal control were successfully established. Based on the optimal SNV-NDF preprocessed spectra, the SDPC-WSP-kNN and SDPC-WSP-PLS-DA methods determined the optimal number of wavelengths Conclusion: These results indicated that Vis-NIR spectroscopy pattern recognition can accurately discriminate between OBI and normal controls' plasma samples. This method is reagent-free, rapid, and simple, making it suitable for large-scale, low-cost rapid screening of OBI. In particular, the proposed few-wavelength model can provide an important reference for the development of small specialized blood analyzers for OBI detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.